Benzylimidazole is commonly used as a procarcinogenic or mutagenic compound. Benzylimidazole was found to induce various cytochrome P-450 (CYP) isozymes including, CYP1A, CYP2B1, CYP3A2 and CYP4A11. The compound has also decreased plasma triglyceride levels and has been a potent inducer of rat liver enzymes. Benzylimidazole has been observed to stimulate three distinct forms of UDP-glucuronosyltransferase in male Wistar rats. In addition, Benzylimidazole has been shown to inhibit TXA Synthase (thromboxane A2 synthase) and to have strong cardiotonic activity similar to the cardiac glycosides, including the absence of effects on rate and resistance to adrenergic beta blockers.
1. Tuttle, R.S., et al. 1975. J. Pharmacol. Exp. Ther. 194: 624-632. PMID: 1159635
2. Lynch, T.J., et al. 1985. Biochem. Pharmacol. 34: 1515-1522. PMID: 2986650
3. Magdalou, J., et al. 1988. Biochem. Pharmacol. 37: 3297-3304. PMID: 2840913
4. Mori, Y., et al. 1993. Mutat. Res. 302: 129-133. PMID: 7684507
5. Mori, Y., et al. 2001. Mutagenesis. 16: 479-486. PMID: 11682638
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.